Paper8637232
Human FLT3/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells.
Rosnet O and 10 others. Leukemia, 1996. Cited by 204 papers, by iCite.
Cite this record
ConductScience Library. Human FLT3/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells. Papers, record 8637232. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/8637232
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Human FLT3/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells.
- PubMed
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Hematopoietic Stem Cells | Major topic |
| Leukemia | Major topic |
| Membrane Proteins | Major topic |
| Neoplastic Stem Cells | Major topic |
| Receptor Protein-Tyrosine Kinases | Major topic |
| Antibodies, Monoclonal | |
| Antigens, CD34 | |
| Burkitt Lymphoma | |
| Cell Membrane | |
| Flow Cytometry | |
| Humans | |
| Leukemia, Myeloid, Acute | |
| Proto-Oncogene Proteins c-kit |
Source PubMed
Cited by95
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 204 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42434847 | QuANTUM-Wild: a Phase III, randomized trial of quizartinib in newly diagnosed FLT3-ITD-negative acute myeloid leukemia. | Future Oncol | 2026 | https://conductscience.org/library/papers/42434847 | PubMed |
| 42305542 | From monoclonals to bispecific T cell engagers: the evolving antibody-based therapy landscape in acute myeloid leukemia. | Front Immunol | 2026 | https://conductscience.org/library/papers/42305542 | PubMed |
| 41576755 | Advancements in targeted therapies for acute myeloid leukemia. | Curr Opin Pharmacol | 2026 | https://conductscience.org/library/papers/41576755 | PubMed |
| 41324594 | FLT3-directed BiTE molecules vs CAR T cells in AML: costimulatory signals mitigate T-cell exhaustion. | Blood Adv | 2026 | https://conductscience.org/library/papers/41324594 | PubMed |
| 41310898 | Emerging strategies in CAR-T cell therapy for acute myeloid leukemia: overcoming heterogeneity and improving safety through dual-antigen targeting. | Exp Hematol Oncol | 2025 | https://conductscience.org/library/papers/41310898 | PubMed |
| 41097772 | T-Cell Engagers in Acute Myeloid Leukemia: Molecular Targets, Structure, and Therapeutic Challenges. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/41097772 | PubMed |
| 41046303 | Elucidating the risk factors and oncogene drivers of acute myeloid leukemia. | Hum Cell | 2025 | https://conductscience.org/library/papers/41046303 | PubMed |
| 39337490 | Tracking Response and Resistance in Acute Myeloid Leukemia through Single-Cell DNA Sequencing Helps Uncover New Therapeutic Targets. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/39337490 | PubMed |
| 39007347 | FLT3/CD99 Bispecific Antibody-Based Nanoparticles for Acute Myeloid Leukemia. | Cancer Res Commun | 2024 | https://conductscience.org/library/papers/39007347 | PubMed |
| 38495876 | Leukemic mutation FLT3-ITD is retained in dendritic cells and disrupts their homeostasis leading to expanded Th17 frequency. | Front Immunol | 2024 | https://conductscience.org/library/papers/38495876 | PubMed |
| 38406539 | CD117 expression predicted FLT3 mutation in T-cell acute lymphoblastic leukemia. | EJHaem | 2024 | https://conductscience.org/library/papers/38406539 | PubMed |
| 38187048 | Overexpression of ABCB1 confers resistance to FLT3 inhibitor FN-1501 in cancer cells: in vitro and in vivo characterization. | Am J Cancer Res | 2023 | https://conductscience.org/library/papers/38187048 | PubMed |
| 37760544 | Mechanisms of Resistance to Small Molecules in Acute Myeloid Leukemia. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/37760544 | PubMed |
| 37587502 | Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease. | J Hematol Oncol | 2023 | https://conductscience.org/library/papers/37587502 | PubMed |
| 37195589 | Update on Small Molecule Targeted Therapies for Acute Myeloid Leukemia. | Curr Treat Options Oncol | 2023 | https://conductscience.org/library/papers/37195589 | PubMed |
| 36762937 | Antibody therapies for the treatment of acute myeloid leukemia: exploring current and emerging therapeutic targets. | Expert Opin Investig Drugs | 2023 | https://conductscience.org/library/papers/36762937 | PubMed |
| 36504722 | PCW-A1001, AI-assisted de novo design approach to design a selective inhibitor for FLT-3(D835Y) in acute myeloid leukemia. | Front Mol Biosci | 2022 | https://conductscience.org/library/papers/36504722 | PubMed |
| 36297550 | Doxorubicin-Loaded Polymeric Micelles Conjugated with CKR- and EVQ-FLT3 Peptides for Cytotoxicity in Leukemic Stem Cells. | Pharmaceutics | 2022 | https://conductscience.org/library/papers/36297550 | PubMed |
| 35923716 | FLT3 inhibitors for acute myeloid leukemia: successes, defeats, and emerging paradigms. | RSC Med Chem | 2022 | https://conductscience.org/library/papers/35923716 | PubMed |
| 35884458 | "FLipping" the Story: FLT3-Mutated Acute Myeloid Leukemia and the Evolving Role of FLT3 Inhibitors. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/35884458 | PubMed |
Genes4
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| FLT3 | 2322 | Swiss-Prot's references | https://conductscience.org/library/genes/2322 | NCBI Gene |
| CD34 | 947 | PubTator's text mining | https://conductscience.org/library/genes/947 | NCBI Gene |
| KIT | 3815 | PubTator's text mining | https://conductscience.org/library/genes/3815 | NCBI Gene |
| RET | 5979 | PubTator's text mining | https://conductscience.org/library/genes/5979 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/8637232
GET https://conductscience.org/api/papers/v1/8637232/cited_by?page=2